US Nephrologists Embrace Current IgA Nephropathy Therapies, Yet a Thriving Pipeline Signals Fierce Market Evolution Ahead : vimarsana.com

Exton, Pennsylvania, Oct. 13, 2023 (GLOBE NEWSWIRE) -- The FDA's recent approvals of Calliditas' Tarpeyo (budesonide) and Travere's Filspari (sparsentan) to treat primary IgA nephropathy (IgAN) have

Related Keywords

Pennsylvania , United States , Meghan Weiss Spherix , Callidita Tarpeyo , Travere Filspari , Hibio Morphosys , Otsuka Visterra , Twitter , Novartis , Spherix Network , Dynamix , Linkedin , Iga Nephropathy , New Drug Application , Patient Chart Dynamix , Launch Dynamix , Chart Dynamix , Global Insights , Spherix Global Insights , Spherix Global Insight , Weiss Spherix Global Insights ,